Jim Boeheim and Cellceutix (CTIX) Team to Fight Cancer
Clinical trials should be starting at Harvard's Dana-Farber Cancer Center in the next two months as Cellceutix looks to validate their laboratory research on Kevetrin, their novel drug in development for the treatment of drug resistant cancers. Yesterday, it was disclosed that Syracuse basketball icon Jim Boeheim has come on board the Cellceutix team in the fight against cancer.
(GCA, DSCO, ADGF) PennyOmega.com Watch List for Wed Mar. 07, 2012
Cellceutix Featured on Front Page of Boston Business Journal
Cellceutix continues to gain industry attention by both investors, big pharma and publications. Their Chief Executive Officer was featured on the front page of Friday's Boston Business Journal. As the clinical trials for Kevetrin should be starting in a couple months at Dana-Farber, attention should continue to increase.
SDIX, CRWE, SBGI, XATA, SEAC Stock Market Report from PennyOtcStock
SDIX? (NASDAQ: SDIX), recently announced that it has successfully completed its previously announced sale of the assets of its water quality division to Modern Water plc for $4.5 million. Modern Water acquired the division's intellectual property, current inventory and commercial contracts, as well as its equipment and staff.
BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) To Present at Three September Healthcare Conferences
Biotech Stock News; Aethlon Medical (OTCBB: AEMD) Announces Cancer Studies
PWRM, NHPR, EEE, AIR, PBT, - CRWESelect.com Stock News! Power3 Medical Products, National Health Partners, Evergreen Energy, AAR
OSIS, PWRM, ROLL, CLNO, TLVT, - CRWESelect.com Stock News! OSI Systems, Power3 Medical Products, RBC Bearings, Cleantech Transit
ENMD, CLNO, PWRM, MTD, PCP, CRM, - CRWESelect.com Stock News! EntreMed, Cleantech Transit, Power3 Medical Products
EntreMed, Inc. (NASDAQ:ENMD)
EntreMed, Inc. is a clinical-stage pharmaceutical company committed to developing ENMD-2076, a selective angiogenic kinase inhibitor, for the treatment of cancer.
ENMD-2076 is currently in a multi-center Phase 2 study in ovarian cancer and in several Phase 1 studies in solid tumors, multiple myeloma, and leukemia.